DNA & SOLUBLE MULTIMERIC IMMUNOGEN FOR HUMMORAL IMMUNITY

脱氧核糖核酸

基本信息

  • 批准号:
    2887880
  • 负责人:
  • 金额:
    $ 18.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-09-29 至 2002-06-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: (Adapted from applicant's abstract): Earlier work in a number of disease models has shown that immunogens containing tandemly repeated epitopes can be more immunogenic than a respective immunogen containing only a single copy of the sequence. The applicant's studies have revealed that antisera raised in mice to a recombinant immunogen in alum containing eight copies of an MN isolate V3PND sequence is able to neutralize ADA, a primary M-tropic isolate of HIV-I. However, despite hopes of generating immunogens able to induce antibodies capable of primary isolate neutralization, the hypervariable nature of the V3 loop of HIV would apparently necessitate incorporation of multiple strain specific V3 loop sequences in any prototype AIDS vaccine. Coincident with the increased understanding of the role of the V3 loop in determining cellular tropism, however, has come new insights into how the V3loop sequences interact with cellular coreceptors in the facilitation of HIV infection. CCR5 is a G-protein coupled receptor identified as integral for entry by M-tropic HIV isolates into macrophages. Since M-tropic viral isolates are especially implicated early in HIV infection and individuals who are homozygous for the 32 bp deletion which results in a non-functional-CCR5 receptor are protected from infection from HIV, yet appear to have a normal phenotype, the CCR5 extracellular receptor sequences represent attractive targets for humoral immunity to HIV-I. We have analyzed the CCR5 extracellular receptor sequence domains and have identified putative extracellular sequences which represent potential antibody targets. The major objectives of the current study are to: a) Develop tandem repeat soluble and DNA constructs representing sequences from the V3 loop of primary NSI M-tropic isolates; b) Analyze the ability of antisera to these constructs raised in BALB/c mice to neutralize homologous and heterologous primary NSI M-tropic HIV isolates; c) Develop tandem repeat soluble and DNA constructs representing sequences from the putative extracellular domains of CCR5; d) Analyze the ability of antisera to these constructs raised in BALB/c mice to neutralize homologous and heterologous primary NSI M-tropic HIV isolates and; e)Utilizing the results from targeting the V3 and CCR5 sequences, construct hybrid immunogens which contain sequences from both the V3 loop of primary NSI M-tropic viruses, and immunogenic sequences from the CCR5 coreceptor. The construction of these immunogens is enabled by our development of BMX7, a novel vector for cloning multi-determinant tandem repeat immunogens, and BMX7EX, a DNA expression vector which retains the essential cloning features of the BMX7 vector. These studies will ideally culminate in the development of immunogens capable of inducing antibodies able to neutralize M-tropic primary isolate infectivity and contribute significantly to our understanding of the immunology of peptide component DNA and soluble immunogens.
描述:(改编自申请人的摘要):早期的工作在一个数字

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JON OSCHERWITZ其他文献

JON OSCHERWITZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JON OSCHERWITZ', 18)}}的其他基金

A multivalent vaccine for Staphylococcus aureus
金黄色葡萄球菌多价疫苗
  • 批准号:
    10515340
  • 财政年份:
    2019
  • 资助金额:
    $ 18.9万
  • 项目类别:
A multivalent vaccine for Staphylococcus aureus
金黄色葡萄球菌多价疫苗
  • 批准号:
    10057219
  • 财政年份:
    2019
  • 资助金额:
    $ 18.9万
  • 项目类别:
A multivalent vaccine for Staphylococcus aureus
金黄色葡萄球菌多价疫苗
  • 批准号:
    10421262
  • 财政年份:
    2019
  • 资助金额:
    $ 18.9万
  • 项目类别:
A molecularly targeted pre- and post-exposure vaccine for anthrax
炭疽暴露前和暴露后分子靶向疫苗
  • 批准号:
    8781529
  • 财政年份:
    2014
  • 资助金额:
    $ 18.9万
  • 项目类别:
A molecularly targeted pre- and post-exposure vaccine for anthrax
炭疽暴露前和暴露后分子靶向疫苗
  • 批准号:
    8889624
  • 财政年份:
    2014
  • 资助金额:
    $ 18.9万
  • 项目类别:
DNA & SOLUBLE MULTIMERIC IMMUNOGEN FOR HUMMORAL IMMUNITY
脱氧核糖核酸
  • 批准号:
    2751241
  • 财政年份:
    1998
  • 资助金额:
    $ 18.9万
  • 项目类别:

相似海外基金

Intelligent cryo-electron microscopy of G protein-coupled receptors
G 蛋白偶联受体的智能冷冻电子显微镜
  • 批准号:
    23K23818
  • 财政年份:
    2024
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Cryo-electron microscopy determination of G protein-coupled receptor states
冷冻电镜测定 G 蛋白偶联受体状态
  • 批准号:
    DE230101681
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Identifying reproductive roles for the Super-conserved Receptors Expressed in Brain (SREB) G protein-coupled receptor family using novel agonists and a comparative fish model
RUI:使用新型激动剂和比较鱼类模型确定脑中表达的超级保守受体 (SREB) G 蛋白偶联受体家族的生殖作用
  • 批准号:
    2307614
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Continuing Grant
Development of multidrug combination molecular targeted therapeutics based on G protein-coupled receptor interactions in glioblastoma
基于G蛋白偶联受体相互作用的胶质母细胞瘤多药组合分子靶向治疗的开发
  • 批准号:
    23K08551
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Role of Intermediate Conformations in G Protein-coupled Receptor Signaling
中间构象在 G 蛋白偶联受体信号传导中的作用
  • 批准号:
    10635763
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
India Link: Selective interactions between G protein-coupled receptors and conformationally selective arrestin variants
India Link:G 蛋白偶联受体与构象选择性抑制蛋白变体之间的选择性相互作用
  • 批准号:
    BB/T018720/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Research Grant
Architecture of inhibitory G protein signaling in the hippocampus
海马抑制性 G 蛋白信号传导的结构
  • 批准号:
    10659438
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
Molecular mechanisms of GPCR/G protein diseases and drug development
GPCR/G蛋白疾病的分子机制及药物开发
  • 批准号:
    23K07998
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research Initiation Award: Exploring Class A G-Protein Coupled Receptors (GPCRs)-Ligand Interaction through Machine Learning Approaches
研究启动奖:通过机器学习方法探索 A 类 G 蛋白偶联受体 (GPCR)-配体相互作用
  • 批准号:
    2300475
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Standard Grant
Allostery-driven G protein selectivity in the adenosine A1 receptor
腺苷 A1 受体中变构驱动的 G 蛋白选择性
  • 批准号:
    BB/W016974/1
  • 财政年份:
    2023
  • 资助金额:
    $ 18.9万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了